Please ensure Javascript is enabled for purposes of website accessibility

ResMed Reports Fiscal Q2 Results, Earnings Up 29%

By Mark Prvulovic - Jan 30, 2020 at 7:44PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This medical device maker reported solid top line growth while edging out Wall Street's expectations.

ResMed (RMD 0.33%) reported its fiscal second-quarter financial results on Thursday afternoon. Revenue for the quarter ending December 31 came in at $736.2 million, which is a 13% increase from last year while just slightly above the $730.0 million expected by Wall Street analysts.

For the most part, the quarterly financial results were pretty solid all around. Net income had gone up by 29%, rising from $124.6 million back last year to the $160.6 million reported in fiscal Q2 2019. Where ResMed truly beat analyst expectations, however, was in its earnings per share (EPS), which came in at $1.10 in comparison to the $1 expected by Wall Street.

A person talking on the phone looking at stock charts on his computer.

Image source: Getty Images.

"We had a strong December quarter with double-digit top-line growth and further gross margin expansion, as well as continued fiscal discipline that resulted in improvements in operating leverage and double-digit growth at the bottom line," said ResMed CEO Mick Farrell.

Further details

Revenue growth for the company has been stronger across North America, with its U.S., Canadian, and Latin American markets having seen revenue growth of 14% in comparison to last year. Despite the high growth rate that many healthcare companies are seeing in Asian markets such as China, ResMed's sales in this market haven't grown as quickly, with revenue in the combined European and Asian markets having grown by just 8%. Software-as-a-Service revenue (SaaS), however, grew by a significant 37%, making it one of the fastest-growing segments in ResMed's business.

Earlier this month, ResMed agreed to pay $37 million to the U.S. Department of Justice (DOJ) to settle five separate whistle-blower lawsuits. Insiders had claimed that the company was paying doctors under the table to use its equipment.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ResMed Inc. Stock Quote
ResMed Inc.
RMD
$216.43 (0.33%) $0.71

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.